These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 23987833)

  • 1. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
    Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
    Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
    J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
    Saponara M; Stacchiotti S; Gronchi A
    Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.
    Barone A; Chi DC; Theoret MR; Chen H; He K; Kufrin D; Helms WS; Subramaniam S; Zhao H; Patel A; Goldberg KB; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(24):7448-7453. PubMed ID: 28774898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
    Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
    Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
    Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
    Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
    Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
    Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
    Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
    Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trabectedin in advanced soft tissue sarcoma: case series.
    Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
    J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
    Jones RL; Maki RG; Patel SR; Wang G; McGowan TA; Shalaby WS; Knoblauch RE; von Mehren M; Demetri GD
    Cancer; 2019 Dec; 125(24):4435-4441. PubMed ID: 31503332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
    Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
    Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
    Hoiczyk M; Grabellus F; Podleska L; Ahrens M; Schwindenhammer B; Taeger G; Pöttgen C; Schuler M; Bauer S
    Int J Oncol; 2013 Jul; 43(1):23-8. PubMed ID: 23652821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.